This study conducted a retrospective pharmacovigilance analysis of EGFR-TKIs using the FDA Adverse Event Reporting System (FAERS) database, aiming to elucidate the risk and characteristics of ILD associated with EGFR-TKI use, thereby providing clinicians with more reliable risk management strategies that could improve treatment outcomes and reduce adverse events in patients. The gene discussed is EGFR; the disease is interstitial lung disease.